Charles Schwab Investment Management Inc. Has $3.89 Million Stake in Ironwood Pharmaceuticals, Inc. $IRWD

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Ironwood Pharmaceuticals by 33.5%, acquiring an additional 663,775 shares in the first quarter, bringing its total to 2,647,015 shares valued at approximately $3.89 million.
• Ironwood Pharmaceuticals reported $0.14 earnings per share (EPS) for the recent quarter, exceeding analysts' expectations of ($0.02), with a revenue of $85.24 million versus an estimate of $62.02 million.
• Analysts have upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating, with a consensus price target of $4.94 per share.

Charles Schwab Investment Management Inc. grew its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 33.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,647,015 shares of the biotechnology company's stock after purchasing an additional 663,775 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.64% of Ironwood Pharmaceuticals worth $3,891,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter valued at about $36,000. MetLife Investment Management LLC lifted its stake in shares of Ironwood Pharmaceuticals by 10.6% in the fourth quarter. MetLife Investment Management LLC now owns 89,255 shares of the biotechnology company's stock valued at $395,000 after buying an additional 8,559 shares during the period. Hsbc Holdings PLC lifted its stake in shares of Ironwood Pharmaceuticals by 88.9% in the fourth quarter. Hsbc Holdings PLC now owns 20,886 shares of the biotechnology company's stock valued at $91,000 after buying an additional 9,828 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Ironwood Pharmaceuticals by 4.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 218,422 shares of the biotechnology company's stock valued at $968,000 after buying an additional 10,149 shares during the period. Finally, ProShare Advisors LLC lifted its stake in shares of Ironwood Pharmaceuticals by 28.9% in the fourth quarter. ProShare Advisors LLC now owns 50,204 shares of the biotechnology company's stock valued at $222,000 after buying an additional 11,267 shares during the period.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $4.94.

Ironwood Pharmaceuticals Price Performance

IRWD remained flat at $1.32 during midday trading on Monday. 548,103 shares of the company's stock were exchanged, compared to its average volume of 1,456,046. The company has a market cap of $214.41 million, a price-to-earnings ratio of -26.39 and a beta of 0.32. Ironwood Pharmaceuticals, Inc. has a 1 year low of $0.53 and a 1 year high of $5.21. The company's 50 day moving average is $0.89 and its 200-day moving average is $1.01.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of ($0.02) by $0.16. The firm had revenue of $85.24 million during the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.